Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Omeros Corporation (OMER)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 717,101
  • Shares Outstanding, K 43,940
  • Annual Sales, $ 41,620 K
  • Annual Income, $ -66,750 K
  • 36-Month Beta 2.96
  • Price/Sales 17.39
  • Price/Cash Flow 0.00
  • Price/Book 0.00

Price Performance

See More
Period Period Low Period High Performance
1-Month
14.22 +14.77%
on 03/29/17
17.19 -5.06%
on 04/10/17
+2.22 (+15.74%)
since 03/28/17
3-Month
9.06 +80.13%
on 01/30/17
17.19 -5.06%
on 04/10/17
+6.88 (+72.88%)
since 01/27/17
52-Week
7.20 +126.67%
on 10/18/16
17.19 -5.06%
on 04/10/17
+2.91 (+21.70%)
since 04/28/16

Most Recent Stories

More News
Osiris Therapeutics Sees Stock Bounce Up On Restatement, Omeros Readies for Presentations of its OMR-721 Candidate Drug

NEW YORK, NY / ACCESSWIRE / March 29, 2017 / Stocks of both companies rose on future-oriented news for investors. While FDA clinical trials continue, both companies are getting positive news coverage...

OSIR : 4.7400 (+0.64%)
OMER : 16.32 (-0.91%)
Omeros and Keryx are Potential Beneficiaries of New Administration Deregulation

NEW YORK, NY / ACCESSWIRE / March 21, 2017 / The current word from market observers is that the biotech sector may have new life breathed into it by a Republican led Congress and the new administration....

KERX : 5.92 (+0.34%)
OMER : 16.32 (-0.91%)
Research Reports Coverage on Biotech Stocks -- VIVUS, Ultragenyx Pharma, Cymabay Therapeutics, and Omeros

This morning, Stock-Callers.com reviews select Biotech equities, namely: VIVUS Inc. (NASDAQ: VVUS), Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), Cymabay Therapeutics Inc. (NASDAQ: CBAY), and Omeros Corp....

RARE : 64.39 (-0.23%)
VVUS : 1.01 (-1.94%)
CBAY : 3.62 (+4.02%)
OMER : 16.32 (-0.91%)
Omeros Reports Additional Positive Results from OMS721 Phase 2 Trial in Patients with Stem Cell Transplant-Associated Thrombotic Microangiopathy

Omeros Corporation (NASDAQ: OMER) today announced additional positive data from the ongoing Phase 2 clinical trial evaluating OMS721 in the treatment of hematopoietic stem cell transplant-associated...

OMER : 16.32 (-0.91%)
Research Reports Coverage on Biotech Stocks -- Anavex Life Sciences, Omeros, Spectrum Pharma, and Lexicon Pharma

Pre-market, Stock-Callers.com monitors the most recent performances of these Biotech stocks: Anavex Life Sciences Corp. (NASDAQ: AVXL), Omeros Corp. (NASDAQ: OMER), Spectrum Pharmaceuticals Inc. (NASDAQ:...

SPPI : 7.61 (-3.18%)
LXRX : 15.61 (unch)
AVXL : 5.63 (-0.71%)
OMER : 16.32 (-0.91%)
How These Biotech Stocks are Faring? -- Inovio Pharma, 22nd Century, Omeros, and Cerulean Pharma

On Tuesday, US markets saw broad based gains with all nine sectors finishing the trading session in green. The NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 also ended yesterday's...

XXII : 1.40 (+2.19%)
CERU : 0.56 (-8.20%)
INO : 6.29 (-2.18%)
OMER : 16.32 (-0.91%)
Omeros Extending Compassionate Use for Pediatric Patient No Longer Requiring Dialysis after OMS721 Treatment

Omeros Corporation (NASDAQ: OMER) today announced that, following physician request, it will provide continued supply of OMS721 for a pediatric patient with hematopoietic stem cell transplant-associated...

OMER : 16.32 (-0.91%)
International Consortium of Complement Experts Receives EUR1.3 Million Grant to Study Role of MASP-2 and Lectin Pathway in Traumatic Brain Injury

Omeros Corporation (NASDAQ: OMER) today announced that an international consortium of complement experts from Italy, United Kingdom, Germany, Spain and Poland was awarded EUR1.3 million in...

OMER : 16.32 (-0.91%)
Omeros Announces Successful Outcome of OMIDRIA(R) Pediatric Cataract Trial

Omeros Corporation (NASDAQ: OMER) today announced the successful outcome of its recently completed post-marketing clinical trial of the effect of OMIDRIA(R) (phenylephrine and ketorolac injection)...

OMER : 16.32 (-0.91%)
How These Biotech Stocks are Faring? -- Alexion Pharma, Progenics Pharma, Omeros, and Chimerix

On Tuesday, all three benchmark US indices were trading positively at the close of the markets. The bullish trend was reflected by broad-based gains in the US markets which saw eight out of nine sectors...

PGNX : 7.92 (+2.59%)
OMER : 16.32 (-0.91%)
ALXN : 127.78 (+0.69%)
CMRX : 5.98 (-2.76%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM)...

See More

Support & Resistance

2nd Resistance Point 16.81
1st Resistance Point 16.57
Last Price 16.32
1st Support Level 16.08
2nd Support Level 15.83

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.